Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective studyResearch in context

Bibliographic Details
Title: Anti-PD-1 therapy plus chemotherapy versus anti-PD-1 therapy alone in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia: a multicenter, retrospective studyResearch in context
Authors: Xiaoyu Wang, Wei Cang, Xiaomei Liu, Yu Cheng, Xirun Wan, Fengzhi Feng, Tong Ren, Jun Zhao, Fang Jiang, Hongyan Cheng, Yu Gu, Lihua Chen, Chen Li, Xiuqin Li, Junjun Yang, Xin Lu, Yang Xiang
Source: EClinicalMedicine, Vol 59, Iss , Pp 101974- (2023)
Publisher Information: Elsevier, 2023.
Publication Year: 2023
Collection: LCC:Medicine (General)
Subject Terms: PD-1 inhibitors, Gestational trophoblastic neoplasia, Combination therapy, Chemotherapy, Medicine (General), R5-920
More Details: Summary: Background: Synergistic antitumor effects of immunotherapy and chemotherapy have been demonstrated in several solid tumors. However, this combination strategy has not been addressed in gestational trophoblastic neoplasia (GTN) cases. We therefore compared the safety and therapeutic effect of anti-programmed cell death 1 (PD-1) therapy combined with chemotherapy versus anti-PD-1 monotherapy among high-risk chemorefractory or relapsed GTN patients. Methods: This retrospective cohort study was conducted at three teaching hospitals in China. Chemorefractory or relapsed GTN cases receiving anti-PD-1 therapy combined with chemotherapy or anti-PD-1 monotherapy were selected from each center between August 2018 and March 2022. Study endpoints included objective response rate (ORR), treatment duration, overall survival (OS) and progression-free survival (PFS). The nature, prevalence and severity of treatment-related adverse events (TRAEs) were evaluated. Findings: This work enrolled 66 cases. Thirty-five and 31 patients received anti-PD-1 therapy alone and combined with chemotherapy, respectively. The combined treatment dramatically increased the objective response rate from 62.9% (22/35) to 96.8% (30/31) (p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2589-5370
Relation: http://www.sciencedirect.com/science/article/pii/S2589537023001517; https://doaj.org/toc/2589-5370
DOI: 10.1016/j.eclinm.2023.101974
Access URL: https://doaj.org/article/1068d68eb7ad463a80875bfff149b0b4
Accession Number: edsdoj.1068d68eb7ad463a80875bfff149b0b4
Database: Directory of Open Access Journals
More Details
ISSN:25895370
DOI:10.1016/j.eclinm.2023.101974
Published in:EClinicalMedicine
Language:English